SCHEMBL267899

SCHEMBL267899

CCN(CC)CCN(CCN(CC)CC)Cc1cccc(C(=O)Nc2ccc(N3CCCCC3)cc2C(=O)NN=Cc2cccc(F)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 3/20 0.48
SLC34A1 Q06495 1/20 0.48
SLC34A3 Q8N130 1/20 0.48
SLC20A1 Q8WUM9 1/20 0.48
SMN1; SMN2 Q16637 5/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
MAPT P10636 3/20 0.41
TP53 P04637 2/20 0.41
TSHR P16473 2/20 0.41
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 3/20 0.38
CYP2C19 P33261 3/20 0.38
CYP3A4 P08684 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ACHE P22303 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267898 1.00 SLC34A2 (0.48) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL267743 0.95 SLC34A2 (0.47) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL267742 0.95 SLC34A2 (0.47) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL267193 0.94 ALDH1A1 (0.44) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL267192 0.94 ALDH1A1 (0.44) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL267758 0.90 ALDH1A1 (0.40) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL267757 0.90 ALDH1A1 (0.40) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL269156 0.90 ALDH1A1 (0.43) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL269157 0.90 ALDH1A1 (0.43) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL267290 0.89 ALDH1A1 (0.43) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SLC34A2 6/4885SLC34A1 4/4885SLC34A3 12/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885SLC34A1 1/4885SLC34A3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.